Autologous vaccine-enhanced ex vivo activated cancer neoantigens-specific T cells TVI-Brain-1

{
  "id": "MLC-T-ONC-011813",
  "term": "Autologous vaccine-enhanced ex vivo activated cancer neoantigens-specific T cells TVI-Brain-1",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T lymphocytes collected from the patient after the administration of a personalized cancer vaccine composed of an attenuated form of patient-specific cancer cells and an immunological adjuvant, via leukapheresis, and activated ex vivo, with potential immunostimulating and antineoplastic activities. Cancer neoantigens-specific T cells are collected after the administration of the personalized cancer vaccine and expanded ex vivo. Upon administration, the autologous vaccine-enhanced ex vivo activated cancer neoantigens-specific T cells TVI-Brain-1 recognize and bind to tumor cells expressing the cancer neoantigens, resulting in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the patient's tumor cells.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-vaccine-enhanced-ex-vivo-activated-cancer-neoantigens-specific-t-tvi/"
}